These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 23883212

  • 1. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
    Kim JY, Lee SS, Byun JH, Kim SY, Park SH, Shin YM, Lee MG.
    AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium.
    Gupta RT, Iseman CM, Leyendecker JR, Shyknevsky I, Merkle EM, Taouli B.
    AJR Am J Roentgenol; 2012 Jul; 199(1):35-43. PubMed ID: 22733891
    [Abstract] [Full Text] [Related]

  • 3. Gadoxetate disodium-enhanced hepatobiliary phase MRI of hepatocellular carcinoma: correlation with histological characteristics.
    Choi JY, Kim MJ, Park YN, Lee JM, Yoo SK, Rha SY, Seok JY.
    AJR Am J Roentgenol; 2011 Aug; 197(2):399-405. PubMed ID: 21785086
    [Abstract] [Full Text] [Related]

  • 4. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.
    Davenport MS, Caoili EM, Kaza RK, Hussain HK.
    Radiology; 2014 Jul; 272(1):123-31. PubMed ID: 24617733
    [Abstract] [Full Text] [Related]

  • 5. Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.
    Kim SY, Wu EH, Park SH, Wang ZJ, Hope TA, Yee J, Zhao LQ, Chang WC, Yeh BM.
    Abdom Radiol (NY); 2016 Aug; 41(8):1522-31. PubMed ID: 26971341
    [Abstract] [Full Text] [Related]

  • 6. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
    Goshima S, Kanematsu M, Watanabe H, Kondo H, Mizuno N, Kawada H, Shiratori Y, Onozuka M, Moriyama N, Bae KT.
    Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
    [Abstract] [Full Text] [Related]

  • 7. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY, Kim SH, Lee WJ, Lim HK.
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [Abstract] [Full Text] [Related]

  • 8. Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
    Choi SH, Lee JM, Yu NC, Suh KS, Jang JJ, Kim SH, Choi BI.
    AJR Am J Roentgenol; 2008 Aug; 191(2):529-36. PubMed ID: 18647927
    [Abstract] [Full Text] [Related]

  • 9. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine.
    Stocker D, Hectors S, Bane O, Vietti-Violi N, Said D, Kennedy P, Cuevas J, Cunha GM, Sirlin CB, Fowler KJ, Lewis S, Taouli B.
    Eur Radiol; 2021 Dec; 31(12):9306-9315. PubMed ID: 34043055
    [Abstract] [Full Text] [Related]

  • 10. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
    Kim HJ, Kim BS, Kim MJ, Kim SH, de Campos RO, Hernandes M, Semelka RC.
    J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
    [Abstract] [Full Text] [Related]

  • 11. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, Merkle EM.
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [Abstract] [Full Text] [Related]

  • 12. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
    Kim JI, Lee JM, Choi JY, Kim YK, Kim SH, Lee JY, Han JK, Choi BI.
    Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma.
    Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR.
    AJR Am J Roentgenol; 2018 Jun; 210(6):1266-1272. PubMed ID: 29629800
    [Abstract] [Full Text] [Related]

  • 14. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH, Kim SH, Park MJ, Park CK, Rhim H.
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [Abstract] [Full Text] [Related]

  • 15. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality.
    Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK.
    Radiology; 2013 Feb; 266(2):452-61. PubMed ID: 23192781
    [Abstract] [Full Text] [Related]

  • 16. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition.
    Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR.
    Radiology; 2014 May; 271(2):426-34. PubMed ID: 24475864
    [Abstract] [Full Text] [Related]

  • 17. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging predicts the histological grade of hepatocellular carcinoma only in patients with Child-Pugh class A cirrhosis.
    Kim HY, Choi JY, Kim CW, Bae SH, Yoon SK, Lee YJ, Rha SE, You YK, Kim DG, Jung ES.
    Liver Transpl; 2012 Jul; 18(7):850-7. PubMed ID: 22407909
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI using MR fluoroscopic triggering and slow injection technique.
    Goshima S, Kanematsu M, Kondo H, Watanabe H, Kawada H, Moriyama N, Bae KT.
    AJR Am J Roentgenol; 2013 Sep; 201(3):578-82. PubMed ID: 23971449
    [Abstract] [Full Text] [Related]

  • 19. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
    Rong D, He B, Tang W, Xie S, Kuang S, Grazioli L, Hussain SM, Yang Y, Wang J.
    AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
    [Abstract] [Full Text] [Related]

  • 20. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ, Kim MJ, Choi JY, Park YN, Park MS, Kim KW.
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.